Dr. Tony Talebi discusses the Treatment of Locally Advanced Kidney Cancer with Dr Merchan.

Dr. Tony Talebi discusses the Treatment of Locally Advanced Kidney Cancer with Dr. Merchan. For further discussion visit http://www.HemOnc101.com

Treatment of locally advanced stage 1 to 3 kidney cancer


Kidney cancer or Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary kidney (renal) neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare.

Patients with kidney cancer or RCC can present with a range of symptoms; unfortunately, many patients are asymptomatic until the disease is advanced. At presentation, approximately 25 percent of individuals either have distant metastases or advanced locoregional disease.

Patients with localized disease can present with a wide array of symptoms and/or laboratory abnormalities, or they may be diagnosed incidentally. The most common presenting symptoms were blood in the urine (hematuria), abdominal mass, pain, and weight loss.

For patients with isolated, solid kidney masses, resection with either a partial or complete nephrectomy is preferred to biopsy because it provides both the diagnosis and definitive treatment.

Here, Dr. Tony Talebi discusses the treatment of locally advanced stage 1 to 3 kidney cancer (RCC) with Dr. Jaime Merchan, an assistant professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including symptoms, diagnosis, staging, surgery, RFA, high dose IL-2, and chemotherapy treatment for kidney cancer or renal cell carcinoma.

Dr. Jaime Merchan credentials:

Certifications American Board of Internal Med-Hematology American Board of Internal Med-Medical Oncology
Specialties
Internal Medicine
Hematology/Oncology - Internal Medicine
Roles
Assistant Professor of Clinical Medicine
Clinical Interests
Gastrointestinal and Genitourinary Malignancies
Research Interests
Tumor Angiogenesis, vascular targeting, experimental therapeutics

Education
2003 Masters
Harvard Medical School and Massachusetts Institute of Technology
1998 Fellowship
Beth Israel Deaconess Med Ctr/Harvard Medical School
1997 Chief Resident
U of Miami/VA Medical Center
1995 Residency
U of Miami/Jackson Memorial Med Center
1994 Internship
U of Miami/Jackson Memorial Med Ctr
1992 M.D.
Universidad Catolica de Santiago de Guayaquil

Category:

Entertainment

Tags:

• hemonc101